594 related articles for article (PubMed ID: 36171009)
1. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
2. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Laza-Briviesca R; Cruz-Bermúdez A; Nadal E; Insa A; García-Campelo MDR; Huidobro G; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Casarrubios M; Sierra-Rodero B; Tarín C; García-Grande A; Haymaker C; Wistuba II; Romero A; Franco F; Provencio M
Clin Transl Med; 2021 Jul; 11(7):e491. PubMed ID: 34323406
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
5. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM; Spicer J; Lu S; Provencio M; Mitsudomi T; Awad MM; Felip E; Broderick SR; Brahmer JR; Swanson SJ; Kerr K; Wang C; Ciuleanu TE; Saylors GB; Tanaka F; Ito H; Chen KN; Liberman M; Vokes EE; Taube JM; Dorange C; Cai J; Fiore J; Jarkowski A; Balli D; Sausen M; Pandya D; Calvet CY; Girard N;
N Engl J Med; 2022 May; 386(21):1973-1985. PubMed ID: 35403841
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Casarrubios M; Cruz-Bermúdez A; Nadal E; Insa A; García Campelo MDR; Lázaro M; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; de Castro-Carpeño J; Cobo M; López-Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Barquín M; Laza-Briviesca R; Sierra-Rodero B; Parra ER; Sanchez-Espiridion B; Rocha P; Kadara H; Wistuba II; Romero A; Calvo V; Provencio M
Clin Cancer Res; 2021 Nov; 27(21):5878-5890. PubMed ID: 34376534
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
[TBL] [Abstract][Full Text] [Related]
9. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
11. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Sato M; Watanabe S; Tanaka H; Nozaki K; Arita M; Takahashi M; Shoji S; Ichikawa K; Kondo R; Aoki N; Hayashi M; Ohshima Y; Koya T; Ohashi R; Ajioka Y; Kikuchi T
PLoS One; 2019; 14(4):e0215292. PubMed ID: 30978241
[TBL] [Abstract][Full Text] [Related]
13. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV; Harpole D; Mitsudomi T; Taube JM; Galffy G; Hochmair M; Winder T; Zukov R; Garbaos G; Gao S; Kuroda H; Ostoros G; Tran TV; You J; Lee KY; Antonuzzo L; Papai-Szekely Z; Akamatsu H; Biswas B; Spira A; Crawford J; Le HT; Aperghis M; Doherty GJ; Mann H; Fouad TM; Reck M;
N Engl J Med; 2023 Nov; 389(18):1672-1684. PubMed ID: 37870974
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Liu SY; Dong S; Yang XN; Liao RQ; Jiang BY; Wang Q; Ben XS; Qiao GB; Lin JT; Yan HH; Yan LX; Nie Q; Tu HY; Wang BC; Yang JJ; Zhou Q; Li HR; Liu K; Wu W; Liu SM; Zhong WZ; Wu YL
Signal Transduct Target Ther; 2023 Dec; 8(1):442. PubMed ID: 38057314
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Forde PM; Chaft JE; Smith KN; Anagnostou V; Cottrell TR; Hellmann MD; Zahurak M; Yang SC; Jones DR; Broderick S; Battafarano RJ; Velez MJ; Rekhtman N; Olah Z; Naidoo J; Marrone KA; Verde F; Guo H; Zhang J; Caushi JX; Chan HY; Sidhom JW; Scharpf RB; White J; Gabrielson E; Wang H; Rosner GL; Rusch V; Wolchok JD; Merghoub T; Taube JM; Velculescu VE; Topalian SL; Brahmer JR; Pardoll DM
N Engl J Med; 2018 May; 378(21):1976-1986. PubMed ID: 29658848
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Provencio M; Nadal E; Insa A; García-Campelo MR; Casal-Rubio J; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Pereira E; Royuela A; Casarrubios M; Salas Antón C; Parra ER; Wistuba I; Calvo V; Laza-Briviesca R; Romero A; Massuti B; Cruz-Bermúdez A
Lancet Oncol; 2020 Nov; 21(11):1413-1422. PubMed ID: 32979984
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
20. Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer.
Chinchilla-Tábora LM; Montero JC; Corchete LA; González-Morais I; Del Barco Morillo E; Olivares-Hernández A; Rodríguez González M; Sayagués JM; Ludeña MD
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
